← FDA DRUG APPROVALS

FDA ANDA · ANDA209430

DAPSONE

Sponsor: TARO

APPLICATION
ANDA209430
TYPE
ANDA
ORIGINAL APPROVAL
2019-03-01
LATEST ACTION
2025-04-23
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

DAPSONEDiscontinued
DAPSONE 25MG · TABLET · ORAL
DAPSONEDiscontinued
DAPSONE 100MG · TABLET · ORAL

Approval history

2025-04-23Labeling · Supplement 1 · standardAP
2019-03-01UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →